

September 04, 2018

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Mumbai – 400 051

BSE Limited
1st Floor, Rotunda Building,
Dalal Street, Fort, Mumbai – 400 001

Sub: Receipt of approval of the Competition Commission of India in connection with notice filed by Procter & Gamble Overseas India B.V.

Dear Sir,

We have been informed on September 3, 2018 that the Competition Commission of India has passed an order under Section 31(1) of the Competition Act, 2002 (*Act*) dated 24 July 2018 in a notice filed by Procter & Gamble Overseas India B.V. under Section 6(2) of the Act, approving the transaction involving *inter alia* the proposed acquisition by Procter & Gamble Overseas India B.V. of 51.8% of the equity share capital of the Company and the proposed transfer of the non-consumer health business of the Company to Merck Life Science Pvt. Ltd. or any of its affiliates on a going concern basis by way of slump sale. We are making this announcement pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and record.

Thanking you,

Yours faithfully

For Merck Limited



Vikas R. Gupta
General Counsel & Company Secretary



Merck Limited

Registered Office
Godrej One, 8th Floor, Pirojshanagar
Eastern Express Highway, Vikhroli East
Mumbai 400079, India.
Phone +91 22 62109000
Fax +91 22 62109999
www.merck.co.in
CIN: L99999MH1967PLC013726

